Industry experts discuss the trends reshaping biotech and biopharma development – from complex modalities and manufacturing pressures to AI, funding constraints, and the growing need to plan for commercialization earlier
To explore current trends shaping the development, manufacturing, and commercialization in biotech and biopharma.
Approach:
Industry Insights: Industry leaders share perspectives on the evolving landscape of biotech and biopharma, focusing on complexities in development and commercialization.
Key Findings:
Molecules are becoming more complex, particularly with formats such as bispecifics and fragments, increasing demands on development and manufacturing.
Companies are prioritizing partners with deep technical knowledge and proven experience within specific modalities.
There is a shift towards asset-specific development strategies to generate early clinical data that informs next steps.
The funding environment is challenging, emphasizing capital efficiency and the ability to demonstrate a credible path to commercialization.
Geopolitical uncertainties and supply chain disruptions pose ongoing risks, reinforcing the importance of building flexibility and risk mitigation into strategies.
Interpretation:
Limitations:
The funding environment remains constrained, particularly for emerging biotechs, and there is a need for flexibility and risk mitigation in development and manufacturing strategies.
